[1]李春睿,吴燕,徐书杭,等.SGLT2抑制剂在2型糖尿病合并阿尔茨海默病中作用的研究进展[J].国际内分泌代谢杂志,2023,43(06):496-499.[doi:10.3760/cma.j.cn121383-20220729-07064]
　Li Chunrui,Wu Yan,Xu Shuhang,et al.Research progress of the effect of sodium glucose cotransporter 2 inhibitors in Alzheimer's disease[J].International Journal of Endocrinology and Metabolism,2023,43(06):496-499.[doi:10.3760/cma.j.cn121383-20220729-07064]
点击复制

SGLT2抑制剂在2型糖尿病合并阿尔茨海默病中作用的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年06期
页码:
496-499
栏目:
综述
出版日期:
2023-11-20

文章信息/Info

Title:
Research progress of the effect of sodium glucose cotransporter 2 inhibitors in Alzheimer's disease
作者:
李春睿1; 吴燕1; 徐书杭2; 刘超2
1阳光融和医院内分泌科,潍坊 261061; 2南京中医药大学附属中西医结合医院内分泌科,南京 210028
Author(s):
Li Chunrui1;  Wu Yan1;  Xu Shuhang2;  Liu Chao2.
1Department of Endocrinology, Sunshine Union Hospital, Weifang 261061, China; 2Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 2
关键词:
糖尿病;  动脉粥样硬化;  认知障碍;  阿尔茨海默病
Keywords:
Diabetes;  Atherosclerosis;  Cognitive impairment;  Alzheimer's disease
DOI:
10.3760/cma.j.cn121383-20220729-07064
摘要:
钠-葡萄糖协同转运蛋白(sodium-dependent glucose transporters,SGLT)2抑制剂不仅广泛应用于糖尿病的治疗,还在多项动物试验及临床试验中表现出预防动脉粥样硬化、改善认知障碍等作用,有望改善2型糖尿病合并阿尔茨海默病患者的预后。其机制包括抗炎、增加脑源性神经营养因子、抑制乙酰胆碱酯酶、减轻氧化应激和改善线粒体功能障碍、恢复分解代谢和合成代谢之间的平衡等。
Abstract:
Sodium dependent glucose transporters(SGLT)- 2 inhibitors are not only widely used in the treatment of diabetes, but also have shown the role of preventing atherosclerosis and improving cognitive impairment in many animal and clinical trials, which is expected to improve the prognosis of type 2 diabetes patients with Alzheimer's disease. Its mechanisms include anti inflammation, increasing brain-derived neurotrophic factor, inhibiting acetylcholinesterase, alleviating oxidative stress and improving mitochondrial dysfunction, restoring the balance between catabolism and anabolism, etc.

参考文献/References:

[1] Nguyen TT,Ta QTH,Nguyen TKO,et al.Type 3 diabetes and its role implications in Alzheimer's disease[J].Int J Mol Sci,2020,21(9):3165.DOI:10.3390/ijms21093165.
[2] Nguyen T,Wen S,Gong M,et al.Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice[J].Diabetes Metab Syndr Obes,2020,13:2781-2799.DOI:10.2147/DMSO.S258593.
[3] Oerter S,Förster C,Bohnert M.Validation of sodium/glucose cotransporter proteins in human brain as a potential marker for temporal narrowing of the trauma formation[J].Int J Legal Med,2019,133(4):1107-1114.DOI:10.1007/s00414-018-1893-6.
[4] Sebastiani A,Greve F,Gölz C,et al.RS1(Rsc1A1)deficiency limits cerebral SGLT1 expression and delays brain damage after experimental traumatic brain injury[J].J Neurochem,2018,147(2):190-203.DOI:10.1111/jnc.14551.
[5] Pawlos A,Broncel M,Woz'niak E,et al.Neuroprotective effect of SGLT2 inhibitors[J].Molecules,2021,26(23):7213.DOI:10.3390/molecules26237213.
[6] Wingo AP,Fan W,Duong DM,et al.Shared proteomic effects of cerebral atherosclerosis and Alzheimer's disease on the human brain[J].Nat Neurosci,2020,23(6):696-700.DOI:10.1038/s41593-020-0635-5.
[7] Irace C,Casciaro F,Scavelli FB,et al.Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy[J].Cardiovasc Diabetol,2018,17(1):52.DOI:10.1186/s12933-018-0695-y.
[8] Hierro-Bujalance C,Infante-Garcia C,Del Marco A,et al.Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes[J].Alzheimers Res Ther,2020,12(1):40.DOI:10.1186/s13195-020-00607-4.
[9] Low S,Goh KS,Ng TP,et al.Association between use of sodium-glucose co-transporter-2(SGLT2)inhibitors and cognitive function in a longitudinal study of patients with type 2 diabetes[J].J Alzheimers Dis,2022,87(2):635-642.DOI:10.3233/JAD-215678.
[10] Wium-Andersen IK,Osler M,Jørgensen MB,et al.Antidiabetic medication and risk of dementia in patients with type 2 diabetes:a nested case-control study[J].Eur J Endocrinol,2019,181(5):499-507.DOI:10.1530/EJE-19-0259.
[11] Arafa NMS,Ali EHA,Hassan MK.Canagliflozin prevents scopolamine-induced memory impairment in rats:comparison with galantamine hydrobromide action[J].Chem Biol Interact,2017,277:195-203.DOI:10.1016/j.cbi.2017.08.013.
[12] Bi C,Fu Y,Li B.Brain-derived neurotrophic factor alleviates diabetes mellitus-accelerated atherosclerosis by promoting M2 polarization of macrophages through repressing the STAT3 pathway[J].Cell Signal,2020,70:109569.DOI:10.1016/j.cellsig.2020.109569.
[13] Liu Z,Ma X,Ilyas I,et al.Impact of sodium glucose cotransporter 2(SGLT2)inhibitors on atherosclerosis:from pharmacology to pre-clinical and clinical therapeutics[J].Theranostics,2021,11(9):4502-4515.DOI:10.7150/thno.54498.
[14] Heerspink HJL,Perco P,Mulder S,et al.Canagliflozin reduces inflammation and fibrosis biomarkers:a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease[J].Diabetologia,2019,62(7):1154-1166.DOI:10.1007/s00125-019-4859-4.
[15] Lee SG,Lee SJ,Lee JJ,et al.Anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2(SGLT-2)inhibitor in a normoglycemic rabbit model[J].Korean Circ J,2020,50(5):443-457.DOI:10.4070/kcj.2019.0296.
[16] Lee N,Heo YJ,Choi SE,et al.Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-Stimulated macrophage via the IKK/NF-κB,MKK7/JNK,and JAK2/STAT1 signalling pathways[J].J Immunol Res,2021,2021:9944880.DOI:10.1155/2021/9944880.
[17] Iannantuoni F,M de Marañon A,Diaz-morales N,et al.The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes[J].J Clin Med,2019,8(11):1814.DOI:10.3390/jcm8111814.
[18] Sa-Nguanmoo P,Tanajak P,Kerdphoo S,et al.SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction,insulin resistance,inflammation,and apoptosis in HFD-induced obese rats[J].Toxicol Appl Pharmacol,2017,333:43-50.DOI:10.1016/j.taap.2017.08.005.
[19] Stanciu GD,Rusu RN,Bild V,et al.Systemic actions of SGLT2 inhibition on chronic mTOR activation as a shared pathogenic mechanism between Alzheimer's disease and diabetes[J].Biomedicines,2021,9(5):576.DOI:10.3390/biomedicines9050576.
[20] Hierro-Bujalance C,Infante-Garcia C,Del Marco A,et al.Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes[J].Alzheimers Res Ther,2020,12(1):40.DOI:10.1186/s13195-020-00607-4.

相似文献/References:

[1]郑少雄.罗格列酮和心血管风险——近期文献解读[J].国际内分泌代谢杂志,2007,(04):231.
[2]凌厉,朱本章.胰岛素类似物安全性研究进展[J].国际内分泌代谢杂志,2007,(04):234.
[3]李颖,刘东方.餐后1小时血糖升高的意义及干预[J].国际内分泌代谢杂志,2007,(04):235.
[4]崔巍,施秉银.内质网应激介导β细胞生存/死亡的研究进展[J].国际内分泌代谢杂志,2007,(04):256.
[5]杨叶虹,胡仁明.SELDI-TOF-MS技术及其在糖尿病研究中的应用[J].国际内分泌代谢杂志,2007,(04):261.
[6]高妍.针对华人糖尿病特点优化降糖方案[J].国际内分泌代谢杂志,2007,(04):269.
[7]杨志霞,郭莹辉,杨永生,等.胰岛素泵和多次皮下注射治疗糖尿病的比较[J].国际内分泌代谢杂志,2007,(04):273.
[8]周建英,马向华.胃旁路术减肥同时改善糖代谢的机制[J].国际内分泌代谢杂志,2007,(04):285.
[9]李翠柳,朱大龙.破译肠道代谢信息,驱动治疗革新[J].国际内分泌代谢杂志,2014,(06):383.[doi:10.3760/cma.j.issn.1673-4157.2014.06.006]
　Li Cuiliu*,Zhu Dalong..Deciphering metabolic messages from the gut drives therapeutic innovation[J].International Journal of Endocrinology and Metabolism,2014,(06):383.[doi:10.3760/cma.j.issn.1673-4157.2014.06.006]
[10]袁捷 姜云生 杜彦丽 王肃.1型糖尿病对小鼠早孕时期子宫肌层结构和细胞增殖的影响[J].国际内分泌代谢杂志,2015,(01):6.[doi:10.3760/cma.j.issn.1673-4157.2015.01.002]
　Yuan JieJiang YunshengDu YanliWang Su.Effects of type 1 diabetes on the muscularis structure and cell proliferation of uterine in mice during early pregnancy[J].International Journal of Endocrinology and Metabolism,2015,(06):6.[doi:10.3760/cma.j.issn.1673-4157.2015.01.002]

备注/Memo

备注/Memo:
通信作者:徐书杭,Email:shuhangxu@163.com
更新日期/Last Update: 2023-12-30